Spexis AG
SIX:SPEX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Footway Group AB
STO:FOOT PREF
|
SE |
Spexis AG
Operating Income
Spexis AG
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Spexis AG
SIX:SPEX
|
Operating Income
-CHf20.5m
|
CAGR 3-Years
21%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Operating Income
-$568.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-36%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Operating Income
CHf51.5m
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Operating Income
-CHf116.4m
|
CAGR 3-Years
47%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Operating Income
CHf8.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Operating Income
-CHf19.6m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-66%
|
CAGR 10-Years
N/A
|
|
Spexis AG
Glance View
Spexis Ltd. is clinical stage biopharmaceutical company, which engages in the research and development of macrocycle drugs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2018-05-15. The firm focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The firm's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
See Also
What is Spexis AG's Operating Income?
Operating Income
-20.5m
CHF
Based on the financial report for Dec 31, 2023, Spexis AG's Operating Income amounts to -20.5m CHF.
What is Spexis AG's Operating Income growth rate?
Operating Income CAGR 5Y
13%
Over the last year, the Operating Income growth was -10%. The average annual Operating Income growth rates for Spexis AG have been 21% over the past three years , 13% over the past five years .
